<DOC>
	<DOC>NCT02175017</DOC>
	<brief_summary>The objective of the study is to investigate the efficacy and safety of ONO-4538 in subjects with stage IIIB/IV or recurrent non-small cell lung cancer unsuited to radical radiotherapy and resistant to a platinum-based chemotherapeutic regimen.</brief_summary>
	<brief_title>ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>1. Male or female â‰¥ 20 years of age 2. Histologically or cytologically confirmed nonsmall cell lung cancer 3. Diagnosis of NSCLC in stage IIIB/IV unsuited to radical radiotherapy according to UICCTNM classification (7th edition) or recurrent NSCLC 4. Has at least one measurable lesion, as defined by the RECIST guideline (version 1.1) 1. Current or prior severe hypersensitivity to another antibody product 2. Multiple primary cancers</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>ONO-4538</keyword>
	<keyword>Advanced non-small cell lung cancer</keyword>
</DOC>